{
    "success": true,
    "data": {
        "id": 1840637,
        "msgid": "bpom-strengthens-downstreaming-to-position-indonesia-as-asia-pacific-atmp-hub-1783162379",
        "date": "2026-07-04 17:04:28",
        "title": "BPOM Strengthens Downstreaming to Position Indonesia as Asia-Pacific ATMP Hub",
        "author": "",
        "source": "ANTARA_ID",
        "tags": "",
        "topic": "Health",
        "summary": "Indonesia's Food and Drug Authority (BPOM) is accelerating the downstreaming of stem cell therapies by enforcing good manufacturing practices to establish the country as a hub for Advanced Therapy Medicinal Products (ATMP) in the Asia-Pacific. The global ATMP market is projected to more than double to USD 86.76 billion by 2031, prompting a push for a robust ecosystem integrating research, regulation, and international collaboration. BPOM is currently providing regulatory assistance to 43 stem cell facilities and collaborating with 186 universities to ensure safety and quality standards are met.",
        "content": "<p>The Food and Drug Authority (BPOM) is strengthening the downstreaming\nof stem cell therapy from the laboratory to clinical application through\nthe implementation of good manufacturing practice (GMP) as an effort to\nmake Indonesia a centre for the development of Advanced Therapy\nMedicinal Products (ATMP) in the Asia-Pacific. BPOM Head Taruna Ikrar\nstated that globally, gene therapy, cell therapy, and ribonucleic acid\n(RNA)-based therapy are developing rapidly, with 4,164 products under\ndevelopment and 148 products having received approval in various\ncountries. The market value of the ATMP industry is even projected to\nmore than double from USD 41.46 billion (Rp697.73 trillion) in 2026 to\nUSD 86.76 billion (Rp1,460 trillion) in 2031. \u201cThis development shows\nthat regenerative medicine is the future of healthcare. Indonesia must\nbe ready to become part of this development through an adaptive\nregulatory system while still ensuring patient safety,\u201d he said in\nJakarta on Saturday. He stated that Indonesia has a significant\nopportunity to become a centre for ATMP and regenerative medicine\ndevelopment in the Asia-Pacific region. For this, a strong ecosystem is\nneeded, ranging from research, regulation, and industry to international\ncollaboration. However, he noted that the biggest challenge in\ndeveloping regenerative therapies is not only scientific innovation but\nalso ensuring that every product has strong evidence of safety,\nefficacy, and quality. \u201cMany innovative therapies still face limitations\nin scientific evidence, dose standardisation, consistency of the\nproduction process, and long-term safety monitoring after use by the\npublic,\u201d he said. Taruna explained that to date, Indonesia has five\nGMP-certified stem cell processing facilities developing new medicinal\nproducts. In addition, BPOM has provided GMP regulatory assistance to 43\nstem cell facilities throughout Indonesia as part of accelerating\nnational innovation development. To speed up the birth of national\nhealth innovations, BPOM is developing an Academia-Business-Government\n(ABG) collaboration model. Through this approach, universities play a\nrole in producing research, industry is tasked with downstreaming and\nproduction, while the government ensures the entire process meets\nsafety, efficacy, and quality standards. Currently, BPOM has\ncollaborated with 186 universities in Indonesia and is supported by 270\nGMP-certified pharmaceutical facilities in strengthening the national\ninnovation ecosystem. The agency is also opening up investment\nopportunities and international cooperation in the development of\nregenerative therapies. Taruna conveyed three main messages for the\ndevelopment of regenerative therapy in Indonesia. First, scientific\ndiscovery creates hope, but the application of GMP standards guarantees\nthat products can be produced consistently. Second, clinical evidence\nand pharmacovigilance are the foundation of long-term trust in\ninnovative therapies. Third, the future of regenerative medicine depends\non the ability to transform research results into products that are\nsafe, consistent, and accessible to the public. Executive Board of the\nAmerican Board of Regenerative Medicine (ABRM) Chris Paulus highlighted\nthat the future of regenerative medicine is not only determined by\nscientific progress. More than that, he said, it is also determined by\nthe ability of all parties to build an integrated innovation ecosystem.\nAccording to him, there are six main foundations for building this\necosystem: strengthening education and training, standards and\ncertification, centres of excellence, research and clinical translation,\nglobal collaboration, and biotechnology industry development. He stated\nthat the biggest investment is in human resource education and training.\n\u201cWe need to have an educated workforce. If you only develop products in\nbiotechnology, you will lack the educated workforce to understand how to\nuse these products safely and effectively,\u201d said Chris.<\/p>",
        "url": "https:\/\/jawawa.id\/newsitem\/bpom-strengthens-downstreaming-to-position-indonesia-as-asia-pacific-atmp-hub-1783162379",
        "image": ""
    },
    "sponsor": "Okusi Associates",
    "sponsor_url": "https:\/\/okusiassociates.com"
}